<DOC>
	<DOC>NCT02101073</DOC>
	<brief_summary>The overall aims of the study are: - To assess the bioavailability of single doses of ALX-0061, administered s.c. at three dose levels, using 2 corresponding single i.v. dose levels as reference. - To provide additional information on pharmacokinetics and pharmacodynamics of ALX-0061. - To further determine the safety and tolerability of ALX-0061. - To further evaluate the systemic (serum) immunogenicity of ALX-0061.</brief_summary>
	<brief_title>ALX-0061 Phase I Bioavailability Study in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Key 1. Healthy volunteers. 2. Gender: male or female. 3. Age 18 to 55 years. 4. Body mass index (BMI): 18.0 â‰¥ BMI &lt; 30.0 kg/m2. Key 1. Any active inflammatory condition, or autoimmune disorder such as lupus erythematosus, multiple sclerosis or rheumatoid arthritis (RA). 2. Any current or recent (within 4 weeks prior to dose) signs or symptoms of infection that requires parenteral antibiotic administration. 3. Symptomatic infection, or suspicion thereof in the last 1 week prior to dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>